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Numerous studies demonstrate that the chemopreventive effect of non-steroidal anti-inﬂammatory drugs on colon cancer is
mediated through inhibition of cell growth and induction of apoptosis. For these effects non-steroidal anti-inﬂammatory drugs
have been recently employed as sensitising agents in chemotherapy. We have shown previously that treatments with aspirin
and NS-398, a cyclo-oxygenase-2 selective inhibitor, affect proliferation, differentiation and apoptosis of the human colon
adenocarcinoma Caco-2 cells. In the present study, we have evaluated the effects of aspirin and NS-398 non-steroidal anti-
inﬂammatory drugs on sensitivity of Caco-2 cells to irinotecan (CPT 11) and etoposide (Vp-16) topoisomerase poisons. We
ﬁnd that aspirin co-treatment is able to prevent anticancer drug-induced toxicity, whereas NS-398 co-treatment poorly affects
anticancer drug-induced apoptosis. These effects correlate with the different ability of aspirin and NS-398 to interfere with cell
cycle during anticancer drug co-treatment. Furthermore, aspirin treatment is associated with an increase in bcl-2 expression,
which persists in the presence of the anticancer drugs. Our data indicate that aspirin, but not NS-398, determines a cell cycle
arrest associated with death suppression. This provides a plausible mechanism for the inhibition of apoptosis and increase in
survival observed in anticancer drug and aspirin co-treatment.
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Numerous studies have shown that the chemopreventive effect of
Non-Steroidal Anti-inﬂammatory drugs (NSAIDs) on colon cancer
is mediated through inhibition of cell growth and induction of
apoptosis (Lu et al, 1995; Piazza et al, 1995; Shiff et al, 1995; Arber
et al, 1997). In particular, several investigators have found that
aspirin and other NSAID treatments correlate with a decrease in
cell replication and with an increased proportion of cells arrested
at the G0/G1 phase of the cell cycle (Piazza et al, 1995; Shiff et
al, 1995, 1996; Arber et al, 1997). The molecular mechanisms
responsible for the effect of NSAIDs on cell growth and apoptosis
are controversial, being either related to their ability to inhibit
cyclooxygenase activity and prostaglandin synthesis or independent
from a prostaglandin pathway (Chan et al, 1998; Sheng et al, 1998;
Smith et al, 2000).
More recently, several reports demonstrated that combinations
of different agents for cancer prevention is more effective than
using either a single agent alone (Li et al, 1999; Torrance et al,
2000). Combination therapy is a strategy currently used to treat
cancer and NSAIDs, for their effects on cell growth and apoptosis,
are potential chemotherapeutic agents to be used alone or in
combination with conventional anticancer drugs. Only a few
studies have accurately evaluated this possibility (Lundholm et al,
1994; Sinicrope et al, 1996; Duffy et al, 1998) and more recently
cyclooxygenase-2 (Cox-2) selective inhibitors have been found to
enhance the sensitivity to anticancer drugs (Soriano et al, 1999;
Hida et al, 2000). Thus, the need for an accurate evaluation of
all the potential interactions between these two classes of drugs.
In a previous work we have shown that aspirin treatment may
affect the proliferation, differentiation and apoptosis of the human
colon adenocarcinoma Caco-2 cells; in particular, we observed that,
depending on the doses, aspirin treatment may induce apoptosis
and a signiﬁcant DNA synthesis inhibition associated with a modi-
ﬁcation in the level of the insulin-like growth factor II (IGF-II)
(Ricchi et al, 1997), an autocrine growth factor for this cell line
(Zarrilli et al, 1994, 1996). More recently, we have demonstrated
that NS-398, a Cox-2 selective inhibitor, also affects Caco-2 DNA
synthesis and apoptosis (Di Popolo et al, 2000).
Accumulating evidence suggest that interference with cell cycle
and/or with the intracellular growth factor (receptor)-activated
signal transduction pathways are key modulators of cellular
response to chemotherapeutic agents (Donaldson et al, 1994; Ciar-
diello et al, 1996; Tortora et al, 1997; Chen et al, 1997; De Luca et
al, 1997; Lin et al, 1998). Because aspirin and NS-398 are able to
inhibit cell growth, we asked whether they might modify sensitivity
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rase poisons irinotecan (CPT 11) and etoposide (VP-16) is strictly
cell cycle dependent (Nitiss and Beck, 1996; Goldwasser et al, 1995)
and ultimately activates a pathway of programmed cell death, we
have decided to use these anticancer drugs to evaluate our hypoth-
esis. Irinotecan (CPT 11) was selected also because it is one of the
most active anticancer agent in colon cancer (Rougier et al, 1998).
We have additionally evaluated whether the effect of aspirin and
NS-398 treatments on the sensitivity of Caco-2 cells to anticancer
drugs correlate with any modiﬁcation in the level of the bcl-2
family protein, one of the key regulator factors in apoptosis (Yang
et al, 1995; Korsmeyer 1999).
Here we ﬁnd that, depending on the concentration, NS-398
treatment poorly affects Caco-2 anticancer sensitivity, while aspir-
in treatment, counteracting anticancer drug-induced cell cycle
modiﬁcation and inducing the expression of bcl-2, is able to
substantially alter Caco-2 anticancer drug-induced apoptosis and
overall viability.
MATERIALS AND METHODS
Cell growth and culture
Caco-2 cells were routinely grown in 100 mm plastic dishes at
378C in a humidiﬁed incubator 5% CO2-95% air atmosphere in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with
10% foetal calf serum, glutamine (2 mM), penicillin (100 u ml
71),
and streptomycin (100 mgm l
71) and buffered with N-2-hydroxy-
ethylpiperazine-N'-2-ethane sulphonic acid (HEPES) (20 mM).
Caco-2 cells were seeded at 5 6 10
4 cells ml
71 and were routinely
sub-cultured when about 80% conﬂuent. The culture medium was
changed every other day. Conﬂuence was reached 6–8 days after
the inoculum and the stationary phase on day 10. Cell cultures
were stopped after 15 passages.
Etoposide and irinotecan were a gift from Bristol-Myers-
Squibb (Rome, Italy) and Rhone Poulen, respectively; anticancer
drugs were diluted in DMEM to prepare 5006 concentrated
solutions. Aspirin (Sigma, Milan, Italy) was dissolved in a
0.1 M Tris-HCl pH 7.8 solution. The solutions were buffered
with Tris base to obtain the ﬁnal pH equal to that of control
DMEM medium and prepared every two weeks. Experiments
were performed in the absence or in the presence of aspirin.
In aspirin untreated cells (control) anticancer drugs were added
for 48 h at day 4 of culture. In treated cells aspirin was added
at day 3 of culture for 24 h. Anticancer drugs were added for
48 h in presence of aspirin or NS 398 (co-treatment) without
changing media.
Cell cycle analysis and apoptosis detection
In order to deﬁne the cell cycle distribution and apoptosis rate,
Caco-2 cells were trypsinised, pelletted, ﬁxed and Propidium Iodide
(PI) stained as previously described (Nicoletti et al, 1991). PI stain-
ing ﬂuorescence of individual cells was analysed by using a FACS
Calibur ﬂow cytometer apparatus (Becton & Dickinson, Mountain
View, CA, USA) and the MODFIT analysis software. For each
sample, at least 20000 events were stored.
Apoptosis/necrosis ratio was additionally evaluated by using
annexin V-FITC/PI double staining technique. Brieﬂy, trypsi-
nized Caco-2 cells were collected, including ﬂoating apoptotic
cells and the cells spontaneously detached during washing
procedure, and annexin V-FITC and PI co-stained by using a
detection kit from Medical & Biological Laboratories Co, Ltd,
Naka-ku Nagoya Japan, according to the manufacturer’s instruc-
tions. Fluorescence analysis was performed by a ﬂow cytometer
apparatus (Becton & Dickinson, Mountain View, CA, USA) and
the Cell Quest analysis software. For each sample, at least
30000 events were stored. Quadrant settings were based on
the negative control. Each experiment was repeated at least
three times.
Plating efﬁciency assay
To determine anticancer drug responsiveness of Caco-2 cells a plat-
ing efﬁciency assay was performed following drug removal. After
each treatment, cells were trypsinised, washed and seeded
(15000 cells 6 well) in triplicate in 24 multiwell cluster dishes
and counted at days 1, 4, 6, 8 and 11 of culture.
Western blot analysis
Mouse monoclonal antibody to Bcl-2 was from Santa Cruz
Biotechnology, Santa Cruz CA, USA. Cells were washed in cold
PBS and lysed for 10 min at 48C with 1 ml of lysis buffer
(50 mM Tris, pH 7.4, 0.5% NP40, 0.01% SDS) containing
protease inhibitors. Lysates from adherent cells collected by
scraping were centrifuged at 12000 g for 15 min at 48C. The
protein concentration in cell lysates was determined by Bio-
Rad Protein Assay (Bio-Rad, Richmond CA, USA) and 50 mg
of total protein from each sample was analysed. Proteins were
separated by a 12% SDS-polyacrylamide gel electrophoresis
and transferred on nitro-cellulose membrane (Hybond-ECL
Nitrocellulose, Amsherman, Rainham, UK). Membranes were
blocked in 5% non-fat dry milk, and after three washes, were
incubated for 1 h at 48C with 0.5 mgm l
71 of mouse monoclo-
nal primary antibody in PBS. After ﬁve washes, ﬁlters were
incubated for 1 h at 48C with horseradish peroxidase-conjugated
anti-mouse secondary antibodies (Bio Rad) diluted 1:2000 in
PBS, 0.2% Tween. The membranes were then washed and
protein bands were detected by an enhanced chemiluminescence
system (Amersham Pharmacia Biotech). Control for loading and
transfer was obtained by probing with anti-a-tubulin (Sigma) at
1:4000 dilution. For quantitation of immunoblots, relative
intensities of bands were quantiﬁed by densitometry with a desk
scanner (Pharmacia Discovery system) and RFLPrint software
(PDI, New York, USA).
Statistical analysis
Statistical comparisons were performed using the Mann–Whitney
U-test. A probability value P50.05 was considered a signiﬁcant
difference.
RESULTS
Effect of aspirin treatment on proliferation and apoptosis
of Caco-2 cells
Our previous data indicated that a 24 h aspirin treatment on Caco-
2 cells at doses ranging from 1 to 10 mM determined a dose-depen-
dent inhibition of DNA synthesis and a signiﬁcant increase in levels
of apoptosis (Ricchi et al, 1997). In the present work, we conﬁrmed
these results on cell growth for a 72 h treatment (data not shown)
and evaluated again the effects on apoptosis by analysing the
percentage of sub-G1 population at ﬂow cytometry. Treatment
with aspirin for 72 h, caused a dose-dependent increase in apopto-
sis starting from the concentration of 5 mM aspirin; the percentage
of apoptotic cells was approximately 6% in control cells and 5, 9
and 12% in cells treated with aspirin at 2, 5 and 10 mM, respec-
tively (data not shown).
The above data suggest that aspirin acts in Caco-2 cells as
anticancer agent with cytostatic properties and ability to induce
apoptosis at high dosages. Therefore we decided to select these
antiproliferative, apoptotic dosages of drugs to study whether
they could modify Caco-2 sensitivity to anticancer drug treat-
ments.
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Vp-16-induced apoptosis
To determine the effect of anticancer drugs on apoptosis, Caco-2
cells were exposed for 48 h at different concentrations of VP-16
and CPT 11 and DNA ploidy was analysed by ﬂow cytometry.
The effects on apoptosis in Caco-2 cells are shown in Figure 1.
Both Vp-16 and CPT 11 dose-dependently increased the levels of
apoptosis in Caco-2 cells: Vp-16 increased apoptosis from 8% at
4.25 mM to 20% at 34 mM (Figure 1A) and CPT 11 increased apop-
tosis from 9% at 5 mM to 16% at 15 mM (Figure 1B). These data
suggest that apoptosis may have a role in drug-induced Caco-2
cells cytotoxicity especially at high concentrations of the drugs.
To evaluate whether aspirin may affect cell killing by topoisome-
rase drugs, we tested a schedule of administration in which the
effects of aspirin treatment on Caco-2 cell growth were present
at moment of anticancer-drug exposure: cells were pre-treated with
aspirin for 24 h and subsequently exposed for 48 h to the afore-
mentioned ranges of drugs in the continuous presence of
NSAIDs (co-treatment). We evaluated the interference of 2 mM
aspirin with anticancer drug induced apoptosis through the analy-
sis of the sub-diploid DNA peak at ﬂow cytometry. As shown in
Figure 1, the levels of apoptosis were reduced for each concentra-
tion of both anticancer drugs when administered in the presence of
aspirin compared with single agent treatment. Aspirin-co-treated
Caco-2 cells were particularly resistant to etoposide-induced apop-
tosis: in fact the percentage of apoptosis in cells co-treated with
aspirin and Vp-16 at 8.5 and 17 mM decreased from 14 to 7%
and from 21 to 9%, respectively. The effect of aspirin on drug-
induced apoptosis was similar when aspirin and anticancer drugs
were simultaneously administered (data not shown). These results
indicate that aspirin-dependent inhibition of proliferation is asso-
ciated with a reduced ability of the drug to induce apoptosis.
To quantify the effects of aspirin co-treatment on Vp-16-
induced apoptosis and to determine whether this effect was present
at concentration in which aspirin was already apoptotic by itself,
we used annexin V-FITC/propidium iodide staining assay. In fact
this assay allows to clearly distinguish viable cells from those
undergoing different stages of apoptosis or necrosis. The effect of
aspirin at 2 and 5 mM concentration on Vp-16-induced toxicity
in Caco-2 cells is analysed in Figure 2. Dot plots of green (Annexin
V-FITC) vs red (PI) ﬂuorescence showed four separate clusters:
viable cell (lower left quadrant), cells at early stage of apoptosis,
(upper left quadrant), cell at late stage of apoptosis (upper right
quadrant), necrotic cells (lower right quadrant). Because of the
high sensitiveness of this procedure, we detected higher levels of
apoptosis as compared to that obtained at the analysis of sub-
diploid peak. Vp-16 at 17 mM increased the percentage of early
and late apoptotic cells from 13 to 48% and decreased the percen-
tage of viable cell from 75 to 49% (Figure 2A,D). Aspirin co-
treatment at 2 and 5 mM dose-dependently decreased the percen-
tage of early and apoptotic cells from 48 to 36 and 18%,
respectively, (Figure 2D vs E,F) and increased the percentage of
viable cells from 49 to 59 and 70% (Figure 2D vs E,F); similar data
were obtained for Vp-16 at 8.5 mM (data not shown) and CPT 11
at 10 mM (Figure 3). Not signiﬁcant change in the levels of necrosis
was observed.
We also evaluated whether the effects of aspirin co-treatment on
anticancer drug responsiveness were unique of Caco-2 cells or were
obtainable in other colon cancer cells showing different Cox
isoform expression proﬁle. We selected the colon cancer cell line
SW480 being Cox-1 positive, but Cox-2 negative (Smith et al,
2000). SW480 cells were co-treated with aspirin and topoisomerase
inhibitors under the above mentioned experimental conditions.
Aspirin co-treatment at 2 and 5 mM decreased both CPT 11-
and VP-16-induced apoptosis. The effect was dose-dependent and
in the same range of magnitude of that obtained in Caco-2 cells
(data not shown).
Effect of NS-398 co-treatment on Vp-16 and
CPT-11-induced apoptosis in Caco-2 cells
Data from our laboratory indicated that Caco-2 cells express Cox-2
but not Cox-1 and NS-398, a COX-2 selective inhibitor, inhibited
DNA synthesis and induced apoptosis in Caco-2 cells (Di Popolo et
al, 2000). To evaluate whether the effects of aspirin co-treatment
on Caco-2 cells were dependent on the inhibition of Cox-2 activity,
we analysed the effect of NS-398 co-treatment on anticancer drug-
induced apoptosis.
We ﬁrstly evaluated the effect on apoptosis of NS-398 72 h
treatment at different concentration using annexin V-FITC/propi-
dium iodide staining assay. As shown in Figure 4, 10 and 50 mM
NS-398 treatment induced higher level of apoptosis compared with
2 and 5 mM aspirin treatments in Caco-2 cells (22 and 25%
compared with 12 and 20%, respectively).
Then we evaluated the effect of NS-398 co-treatment on Vp-16-
and CPT 11-induced toxicity. The percentage of cells in early plus
late apoptosis vs viable cells induced by co-treatments with aspirin
or NS-398 and Vp-16 or CPT 11 are given in Figure 3.
Aspirin at 2 and 5 mM dose-dependently decreased both Vp16-
and CPT 11-induced apoptosis and increased cell viability. NS 398
at 10 mM increased both 17 mM Vp-16- and 10 mM CPT 11-induced
apoptosis (P50.05 and P40.05, respectively), while NS 398 at
50 mM decreased 17 mM Vp-16- and 10 mM CPT 11-dependent
apoptosis (P40.05 and P50.05, respectively). NS 398 at 10 mM
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Figure 1 Effect of 2 mM aspirin co-treatment on VP-16-(A) and CPT
11(B)-induced apoptosis in Caco-2 cells. Cells at day 3 were incubated
with aspirin for 24 h, then anticancer drugs at the indicated concentrations
were added in presence of 2 mM aspirin for 48 h. Apoptosis was calculated
as the percentage of cells showing a sub-diploid DNA peak as described in
Materials and Methods. Data are expressed as mean+s.d.
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treatment with Vp-16- or CPT 11 co-treated cells, while NS 398
at 50 mM increased cell viability of Vp-16-treated cells from 40 to
52% (P50.05). No effects were obtained on anticancer drug
induced-apoptosis with NS 398 at 1 mM (data not shown).
Effect of anticancer drug treatments and anticancer drug
plus aspirin or NS-398 co-treatments on cell cycle
distribution
We examined whether aspirin and NS-398 treatments had any
distinct effect on cell cycle parameter under the same experimental
conditions. The distribution of cells in the phases of the cell cycle is
presented in Table 1. Aspirin treatment was associated with a
modest dose-dependent increase in the proportion of cells in the
S phase, while NS-398 did not signiﬁcantly alter cell cycle para-
meters with respect to control cells.
We also asked whether the different effect of aspirin and NS-398
on survival could be determined by a selective interference with
anticancer drug-induced cell cycle arrest. In fact, Vp-16 arrests cells
in the pre-mitotic phase of the cell cycle leading to accumulation of
the cells in the late S or G2 phase (Fearnhead et al, 1994; Downes
et al, 1994); while CPT 11 causes S phase slowing (Shao et al, 1997;
McDonald and Brown, 1998). Effect of Vp-16 and CPT 11 treated,
Vp-16 and CPT 11 plus aspirin or plus NS-398 co-treated cells
under previously described experimental conditions are shown in
Table 2. We found that Vp-16, from lowest concentration of drug
tested, increased the distribution of Caco-2 cells at the G2 phase of
the cell cycle. In particular, VP-16 at 8.5 mM and 17 mM treatments
were able to trap 85 and 91% of Caco-2 cells in the G2 phase of
cell cycle, respectively. Whereas CPT 11 at 10 and 15 mM treat-
ments accumulated 70 and 85% of Caco-2 cells in the S phase of
cell cycle, respectively (Table 2 and data not shown). Aspirin and
NS-398 co-treatment had different effect on anticancer drug-
induced cell cycle distribution: in cells that have been co-treated
with Vp-16 at 17 mM, aspirin dose-dependently increased the
percentage of Caco-2 cells at G0–G1 phase of cell cycle. NS-398
at 10 mM had no effect on Vp-16-induced accumulation at the
G2 phase of cell cycle, while at 50 mM increased the percentage
of cells at G0–G1 phase from 9 to 15%. In cells that have been
co-treated with aspirin and CPT 11 at 10 mM there was an increase
in the percentage of cells at G0–G1 phase similar to that observed
in Vp-16 co-treated cells. NS-398 only at 50 mM concentration
increased the percentage of cells at G0–G1 phase from 22 to
32% (Table 2).
Effect of aspirin co-treatment on Caco-2 plating efﬁciency
Several reports indicate that cancer cells after a genotoxic treatment
can take hours to many days before dying (Vidair et al, 1996; Han
et al, 1997). To better evaluate the cytoprotective effect of aspirin,
also with respect to potential delayed toxicity of Vp-16, we
measured overall cell viability by performing a plating efﬁciency
assay following 8.5 mM and 17 mM etoposide treatments and co-
treatments with either 2 or 5 mM aspirin (Figure 5A,B). All
replated control Caco-2 cells started to divide after a lag period
of 48h (Figure 5A); they entered into the exponential phase of cell
growth at day 4, and reached the stationary phase at day 14 (data
not shown). Etoposide treatments at both concentrations produced
an approximately 0.7-fold decrease of the cell number at day 4
after replating; the fraction of surviving cells entered into the loga-
rithmic phase of cell growth only at day 8. On the contrary, aspirin
co-treated cells more efﬁciently replated and started the exponen-
tial phase of cell growth at day 6, 5 mM aspirin co-treated cells
showing the best proﬁle of cell growth. Thus, aspirin co-treated
cells appeared to be more viable and less sensitive to anticancer
delayed toxicity. Etoposide at 34 mM was such a toxic treatment
that cell restarted to divide only at day 11; nevertheless, cells co-
treated with aspirin and etoposide also at this concentration,
continued to show an advantage in cell growth (data not shown).
Effect of different treatments on the expression of the bcl-2
protein family
The proteins belonging to the Bcl-2 family are important regulators
of cell death in eukaryotes (Yang et al, 1995; Korsmeyer, 1999).
The apoptotic response of a cell damage by chemotherapy may
depend at least in part, on the balance between proteins which
predispose against genotoxic to programmed cell death such as
bad and bax and proteins which antagonise programmed cell
death, such as bcl-2 and bclx-xl (Yang et al, 1995; Korsmeyer,
1999). To study the mechanisms that mediate the effect of aspirin
and NS-398 on anticancer drugs Caco-2 cell sensitivity, we investi-
gated whether these treatments were associated with a modulation
of the expression of these proteins. Soluble cell lysates were
obtained from control cells and from cell treated with aspirin at
2 and 5 mM and NS-398 at 10 mM and 50 mM doses for 72 h.
Expression of bad, bax and bclx-xl were not affected by any treat-
ment (data not shown); in contrast, more extensive modiﬁcations
were observed in the levels of bcl-2 (Figure 6A): aspirin at 2 and
5m M increased bcl-2 levels dose-dependently by 1.5- and two-fold,
respectively, compared with untreated cells; on the contrary, NS-
398 at 10 mM and 50 mM decreased the levels of bcl-2 by three-
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Figure 2 Effect of aspirin co-treatment on annexin V-FITC/PI staining of
Caco-2 cells. Cells at day 3 were incubated with aspirin for 24 h, then antic-
ancer drugs were added in presence of aspirin for 48 h. Four distinct phe-
notypes become distinguishable: (i) viable cells (lower left quadrant); (ii)
cells at early stage of apoptosis (upper left quadrant); (iii) cells at late stage
of apoptosis (upper right quadrant); (iiii) necrotic cells (lower right quad-
rant). (A) untreated cells; (B) cells treated with 2 mM Aspirin; (C) cells
treated with 5 mM Aspirin; (D) cell treated with 17 mM Vp-16; (E) cells
co-treated with 2 mM aspirin and 17 mM Vp-16; (F) cells co-treated with
5m M aspirin and 17 mM Vp-16. Data represent one of three similar experi-
ments.
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ment increased the ratio bcl-2 to bax determining a pattern of
survival in Caco-2 cells, which was most evident at 5 mM treat-
ment. Then we asked whether etoposide treatment had any effect
on bcl-2 levels: Vp-16 treatment alone decreased bcl-2 levels by
three-fold compared with control cells (Figure 6A); on the
contrary, the levels of bcl-2 were three-fold and ﬁve-fold increased
in cells co-treated with Vp-16 and aspirin at 2 and 5 mM compared
with Vp-16 treated cells, respectively (Figure 6B). bcl-2 levels were
increased by approximately 1.5-fold and two-fold in Vp-16 co-trea-
ted cells with NS 398 at 10 and 50 mM, respectively, compared with
Vp-16 treated cells (Figure 6B). The above all data indicated that
the effects of aspirin and NS-398 treatments on bcl-2 protein
family expression persisted in co-treatment and again were consis-
tent with the effects of aspirin and anticancer drugs
administrations at different doses on apoptosis of Caco-2 cells.
DISCUSSION
Mounting evidence suggest that aspirin and other NSAID are able
to interfere with mitogenic signalling causing arrest of cells in the
G0/G1 phase of the cell cycle and, depending on the doses and the
drug, to induce apoptosis as conventional cytotoxic drugs (Lu et al,
1995; Shiff et al, 1995, 1996; Piazza et al, 1995; Arber et al, 1997).
For these properties NSAIDs have been sporadically employed in
clinical cancer therapy; more frequently, they are utilised as analge-
sic, occasionally concurrently chemotherapy administration
without a profound knowledge of the potential interaction with
anticancer drugs and their efﬁcacy. To date, very little information
has been reported on this subject; a paper describes the ﬁrst exten-
sive screen of commercially available NSAIDs with anticancer drugs
and discusses the potential clinical beneﬁts of such combinations
(Duffy et al, 1998). More recently, several studies have investigated
the possibility of Cox-2 selective inhibitor-mediated enhancement
of chemotherapeutic drug toxicity (Soriano et al, 1999; Hida et
al, 2000). There are not reports comparing the effects of Cox-2
selective inhibition on responsiveness of colon cancer cells to
chemotherapy with that obtained with aspirin, the most frequently
used medicinal drug also for its anti-aggregating properties and in
the clinical treatment of inﬂammatory diseases. In particular, the
use of aspirin for analgesia and antipyresis (650 mg of oral admin-
istration, six times more on average than the anti-platelet dose)
results in peak plasma concentration of 25 mg ml (which corre-
sponds approximately to 0.15 mM). On the other hand, the high
dose of aspirin required for the treatment of arthritis (4–6 g of
oral administration) determines aspirin plasma level up to
300 mg ml, which corresponds to 2 mM (Insel, 2001). The main
purpose of this study is to evaluate if combined treatment in vitro
would produce interactive effects that could be relevant in the clin-
ical use. We have previously demonstrated that aspirin and NS-398
treatments are both associated with the inhibition of proliferation
and induction of apoptosis of Caco-2 cells (Ricchi et al, 1997; Di
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Figure 4 Effect of 2 and 5 mM aspirin and 10 and 50 mM NS-398 72 h
treatment on apoptosis of Caco-2 cells. The percentage of Caco-2 cells
at early and late stages of apoptosis was quantiﬁed as reported in Figure
2. Data points represent the mean of triplicate experiments+s.d.
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apoptosis. Data are expressed as mean+s.d. Data points represent the
mean of triplicate experiments.
Table 1 Cell cycle distribution (per cent) of control and Aspirin- or
NS 398-treated Caco-2 cells
Treatment G0-G1 S G2-M
Control 58 33 9
Asp 2 mM 51 46 3
Asp 5 mM 50 48 2
NS 398 10 mM 62 29 9
NS 398 50 mM 64 29 7
DNA cell cycle analysis was performed by propidium iodide labelling as described in
Material and Methods.
Table 2 Cell cycle distribution (per cent) of Caco-2 cells after anticancer
drug treatments and anticancer drug plus aspirin or NS-398 co-treatments
Treatment G0-G1 S G2-M
Control 58 33 9
Vp-16 17 mM 90 9 1
Asp 2 mM+Vp-16 17 mM 15 0 85
Asp 5 mM+Vp-16 17 mM 37 0 63
NS 10 mM+Vp-16 17 mM 80 9 2
NS 50 mM+Vp-16 17 mM 15 0 85
CPT 11 10 mM 22 70 8
Asp 2 mM+CPT 11 10 mM 22 78 0
Asp 5 mM+CPT 11 10 mM 35 65 0
NS 10 mM+CPT 11 10 mM 15 85 0
NS 50 mM+CPT 11 10 mM 32 68 0
DNA cell cycle analysis was performed by propidium iodide labelling as described in
Materials and Methods.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1501–1509Popolo et al, 2000). Numerous studies suggest that any interference
with mitogenic signalling and cell cycle cause a modiﬁcation in the
responsiveness to conventional cytotoxic drugs. In the present
study, we investigate whether aspirin and NS-398 interference with
cell proliferation has any effect on Caco-2 cells responsiveness to
the topoisomerase poisons irinotecan and etoposide, anticancer
agents that speciﬁcally require DNA synthesis to exert their toxi-
city.
The data reported herein demonstrate that aspirin and NS-398
act as anticancer agents in Caco-2 colon cancer cells with cytostatic
properties and with different ability to induce apoptosis at high
dosages. Also, we show that they differently modify anticancer
responsiveness to chemotherapy of Caco-2 cells. We have evaluated
this effect mainly towards the induction of apoptosis. In fact, there
is emerging evidence that resistance to antitumour treatments relies
on reduced sensitivity to apoptosis induction (Fisher, 1994; Nagata,
1997); in this regard, our results demonstrate that aspirin treat-
ment is able to counteract the proapoptotic effect of anticancer
drugs in vitro.
Aspirin co-treatment produces, at all concentrations investi-
gated, a reduction of anticancer drug-induced apoptosis in Caco-
2 cells and, at 5 mM, a reduction of S/G2 phase cell cycle accumu-
lation. We hypothesise that the effects of high doses of aspirin co-
treatment on anticancer drug-induced toxicity could be mainly
explained by the almost complete inhibition of DNA synthesis
and G1 cell cycle arrest obtained at this dose of aspirin that have
been shown also to alter cell cycle-related proteins (Law et al,
2000; Marra et al, 2000); the reduced ability of such anticancer
drugs to induce apoptosis in quiescent cells have been already
observed (Nitiss and Wang, 1996: Lin et al, 1998). Furthermore,
it is a common observation that agents able to interfere with cell
cycle usually prevent the action of drugs active in the next phase
of cell cycle (Lin et al, 1998).
Moreover, we clearly demonstrate by PI- and annexin V-staining
that the reduced levels of apoptosis obtained in aspirin co-treat-
ments are associated with an increase in cell viability of Caco-2
cells; this effect is also evident by the analysis of plating efﬁciency
in aspirin-Vp 16 co-treated cells; thus, these data indicate that
aspirin co-treatment interferes not only with apoptotic death but
also with overall toxicity induced by these anticancer drugs. In this
regard, aspirin and its metabolite sodium salicylate have been
found to be protective against neurotoxicity elicited by the excita-
tory amino acid glutamate in rat primary neuronal cultures (Grilli
et al, 1996); thus, our data may represent a further evidence of
aspirin cytoprotective property against a cellular damage.
In addition, PI- and annexin V-staining assay indicated that the
cytoptotective effect of aspirin co-treatment is present not only in
Caco-2 cells but also in the Cox-2 negative, Cox-1 positive Sw 480
colon cancer cell line. These data may suggest that aspirin interferes
with topoisomerase poison-induced toxicity through a Cox-inde-
pendent mechanism.
On the other hand, our data show that NS-398 co-treatment
may alternatively reduce or increase anticancer drug induced
apopotosis, depending on the concentration. These effects are less
powerful compared with those observed in the presence of aspirin.
NS-398 at 1mm concentration completely inhibits the biosynthesis
of prostaglandin E2 in Caco-2 cells (Acquaviva et al, unpublished
data) without affecting anticancer drug responsiveness; NS 398,
at 10 mm concentration, causes minimal enhancement of antican-
cer drug-induced apoptosis without modifying cell cycle
parameters. On the contrary, our data show that NS-398, at dose
of 50 mM, is cytoprotective and counteracts anticancer drugs-
induced cell cycle perturbation. Based on these ﬁndings, we postu-
lated that the described effects of increasing dose of NS-398, as in
the case of aspirin, might be dependent on regulation of cell cycle
regulatory protein (Hung et al, 2000) and not related on the inhi-
bition of Cox-2 activity; these data could also reinforce the
hypothesis of the concurrent presence of Cox-2-dependent and
independent mechanisms of action in the antiproliferative effect
of individual selective Cox-2 inhibitors (Gro ¨sch et al, 2001; Smith
et al, 2000).
Several reports suggest that the regulation of the cell response to
chemotherapeutic drugs may also involve a dynamic interplay
among the bcl-2 protein family members (Yang and Korsmeyer,
1996), on which novel treatment approaches have focused to over-
came drug resistance (Strobel et al, 1998a,b; Kobayashi et al, 1998).
In this regard, searching for an alternative and/or complementary
mechanism to cell cycle block, we have evaluated the effect of
aspirin and NS-398 treatment on these proteins. Levels of bax,
bad and bclx-xl are not signiﬁcantly affected by these treatments.
On the contrary, we demonstrate that aspirin treatment is asso-
ciated with a dose dependent increase of bcl-2, that play a
pivotal role extending cell survival through the inhibition of apop-
tosis induced by various stimuli, including chemotherapeutic drugs
(glucocorticoids, alkylating agents, topoisomerase II inhibitors).
The increase in bcl-2 levels is more evident at dose of 5 mM aspir-
in, is detectable in co-treatment and may be responsible for the
induction of a survival signal in Caco-2 cells and for the increase
in viability observed in co-treatments. It has been recently demon-
strated that bcl-2 expression is increased at G1 phase of cell cycle
(Gao and Dou, 2000). Because we have demonstrated that 5 mM
aspirin treatment in the presence of Vp-16 and CPT 11 increases
the percentage of cells at G1 phase, we postulated that the observed
increase of bcl-2 expression might be dependent on a G1 phase
arrest. However, 5 mM aspirin treatment determines a modest
increase in the levels of apoptosis also in the presence of increased
bcl-2 expression; further studies are needed to clarify this phenom-
enon. Moreover, the levels of antiapoptotic bcl-2 protein are
decreased by NS-398 treatment at 10 mM and to a lesser extent at
50 mM. These modiﬁcations persist after anticancer drug treatment
and again strictly correlate with data on apoptosis in co-treatments;
these ﬁndings conﬁrm previous reports showing that bcl-2 protein
levels can affect apoptosis induced by etoposide (Kamesaki et al,
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Figure 5 Effect of 2 and 5 mM aspirin and VP-16 at 8.5 mM (A)o r1 7mM
(B) co-treatments on plating efﬁciency of Caco-2 cells. After each treat-
ment, 15000 cells were seeded in triplicate in 24 multiwell dishes and
counted at day 1, 4, 6, 8 and 11. All data points represent the mean of tri-
plicate experiments.
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British Journal of Cancer (2002) 86(9), 1501–1509 ã 2002 Cancer Research UK1993; Dole et al, 1994). Further studies are needed to investigate if
the effects we observed in vitro are speciﬁc for a cancer cell type
and for phase speciﬁc anticancer agents or are a more general
phenomenon reproducible in vivo also for the aspirin metabolite
salicylate. In fact, preliminary reports indicate that this aspirin
metabolite also affects cell growth (Elder et al, 1996).
Finally our data prompt to accurately investigate all the possible
interference between aspirin or others NSAID and anticancer drugs
and other genotoxic damages in vivo and in vitro. Our ﬁnding may
have important implications for treatment schedules involving both
cytotoxic agents and aspirin in malignancies; they could suggest to
absolutely avoid co-treatment of aspirin and anticancer drugs. On
the other hand, they could also provide a rationale for novel stra-
tegies of enhancement of chemotherapy activity: in fact, Cox-2
selective inhibition could be a feasible and not toxic tool to
increase chemotherapy effectiveness.
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